Evaluation of the effect of enhanced immunization in adults: A cross-sectional study in the southeast city of China

Hum Vaccin Immunother. 2022 Nov 30;18(6):2096972. doi: 10.1080/21645515.2022.2096972. Epub 2022 Jul 25.

Abstract

The efficacy of hepatitis B vaccination in adults was evaluated by comparison of the positive seroprotection rates and the hepatitis B surface antibody (anti-HBs) geometric mean titers (GMTs) between intensive intervention areas and non-intensive intervention areas after 8 years post-vaccination in the Zhejiang province. Seven cities (towns) in Zhejiang province were selected as intensive intervention areas, and adults in the demonstration areas receive hepatitis B vaccine voluntarily and for free. Other areas were non-intensive intervention areas. A total of 3587 participants received the full vaccination course (three doses), and blood samples were withdrawn 8 years after the first vaccination comprised the immunized group, and 2000 participants constituted the control group. The anti-HBs positive seroprotection rates of the immunized and control groups were 65.0% and 53.0%, respectively. The anti-HBs GMT of the subjects in the immunized group was 26.30 mIU/mL compared to 9.33 mIU/mL in the control group (P < .001). Significant differences were detected in the 24-35-, 36-45-, and 46-55-year-old subgroups in the positive seroprotection rates and the anti-HBs GMTs (P < .001) between the immunized and control groups. Moreover, significant differences were found in the anti-HBs GMT in the 46-55-year-old subgroup between the two groups (P = .02), while no differences were observed in the positive seroprotection rate (P = .428). In conclusion, adults who did not receive the hepatitis B vaccine in infancy and had negative serological markers of hepatitis B, especially adults <47-years-old, need vaccination.

Keywords: Hepatitis B virus; adults; enhanced immunization; vaccine.

MeSH terms

  • Adult
  • Cross-Sectional Studies
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Hepatitis B Vaccines*
  • Hepatitis B* / prevention & control
  • Humans
  • Immunization, Secondary
  • Middle Aged
  • Vaccination

Substances

  • Hepatitis B Vaccines
  • Hepatitis B Surface Antigens
  • Hepatitis B Antibodies

Grants and funding

This study was supported by the National Scientific and Technological Major Project of China [2018ZX10715014, 2017ZX10105001, 2014ZX10004008, 2013ZX10004-904, 2011ZX10004-901].